Intratympanic Injection of Edaravone for Idiopathic Sudden Sensorineural Hearing Loss with Profound Hearing Loss
The Journal of International Advanced Otology · 22.05.2025 · 21 (3) · 1-7
DOI: 10.5152/iao.2025.251875 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of International Advanced Otology, online erschienen am 22.05.2025. Verfasst von Yoshihiro Nitta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology and Head and Neck Surgery, Kitasato University School of Medicine, Kanagawa, Japan. Hauptthemen laut MEDLINE: Edaravone, Hearing Loss, Sensorineural, Hearing Loss, Sudden, Free Radical Scavengers. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: In Japan, edaravone, a free radical scavenger, is used clinically to reduce neuronal damage after acute cerebral infarction. In this study, a clinical trial has been designed utilizing intratympanic edaravone injection (ITE), which was hypothesized to exhibit high transitivity into the inner ear, with the aim of identifying an improved treatment modality for patients with idiopathic sudden sensorineural hearing loss (ISSHL) presenting with profound hearing loss. METHODS: Between April 2012 and December 2015, 17 patients with ISSHL, with mean hearing levels equal to or greater than 90 dB HL at the time of the initial visit, were treated with ITE. Fourteen patients with ISSHL under the same conditions were extracted, who received intratympanic steroid injection (ITS) in the department between January 2015 and December 2019 as a historical control. The hearing thresholds were compared between the ITE and ITS groups. RESULTS: The improvement between the initial and final hearing levels was significantly greater in the ITE group than in the ITS group at 250- 1000 Hz. The average hearing improvement was 49.1 (± 21.0) dB in ITE group and 35.2 (± 11.8) dB in ITS group, and the degree of improvement was significantly greater in ITE group. No detectable adverse events associated with ITE were observed in patients’ subjective symptoms. CONCLUSION: The final hearing thresholds of patients treated with ITE were significantly better than those of patients treated with ITS. It has been concluded that ITE treatment may be useful in future clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology and Head and Neck Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
- Department of Rehabilitation, School of Allied Health Sciences, Kitasato University, Kanagawa, Japan.
ORCID-Profile: Hajime Sano, Takaomi Kurioka, Taku Yamashita
Zitieren
APA
Nitta, Y., Sano, H., Kurioka, T., & Yamashita, T. (2025). Intratympanic Injection of Edaravone for Idiopathic Sudden Sensorineural Hearing Loss with Profound Hearing Loss. The Journal of International Advanced Otology, 21(3), 1-7. https://doi.org/10.5152/iao.2025.251875
Vancouver
Nitta Y, Sano H, Kurioka T, Yamashita T. Intratympanic Injection of Edaravone for Idiopathic Sudden Sensorineural Hearing Loss with Profound Hearing Loss. The Journal of International Advanced Otology. 2025;21(3):1-7. doi:10.5152/iao.2025.251875
BibTeX
@article{Nitta2025,
author = {Nitta, Yoshihiro and Sano, Hajime and Kurioka, Takaomi and Yamashita, Taku},
title = {Intratympanic Injection of Edaravone for Idiopathic Sudden Sensorineural Hearing Loss with Profound Hearing Loss},
journal = {The Journal of International Advanced Otology},
year = {2025},
volume = {21},
number = {3},
pages = {1--7},
doi = {10.5152/iao.2025.251875}
}
EUVIMED